Tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: a proof-of-concept study

详细信息    查看全文

• 作者：Philipp  ; Jungebluth MD^a ;   ; ⁱ ; Evren  ; Alici MD^b ; Silvia  ; Baiguera PhD^a ; Katarina  ; Le Blanc ProfMD^c ; Pontus  ; Blomberg PhD^j ; Bé ; la  ; Bozó ; ky MD^k ; Claire  ; Crowley MSc^o ; Oskar  ; Einarsson MD^p ; Karl-Henrik  ; Grinnemo MD^a ;   ; ^l ; Tomas  ; Gudbjartsson ProfMD^q ; Sylvie  ; Le Guyader PhD^d ; Gert  ; Henriksson MDⁱ ; Ola  ; Hermanson PhD^e ; Jan Erik  ; Juto MDⁱ ; Bertil  ; Leidner MD^f ;   ; ^m ; Tobias  ; Lilja PhD^e ; Jan  ; Liska MD^l ; Tom  ; Luedde MD^r ; Vanessa  ; Lundin MS^g ; Guido  ; Moll MS^c ; Bo  ; Nilsson ProfMD^s ; Christoph  ; Roderburg MD^r ; Staffan  ; Strö ; mblad ProfPhD^d ; Tolga  ; Sutlu BSc^b ; Ana Isabel  ; Teixeira PhD^g ; Emma  ; Watz MD^c ;   ; ⁿ ; Alexander  ; Seifalian ProfPhD^o ; Paolo  ; Macchiarini ProfMD^a ;   ; ^h ;   ; ⁱ ;   ; ^{paolo.macchiarini@ki.se}
• 刊名：The Lancet
• 出版年：2011
• 出版时间：10-16 December 2011
• 年：2011
• 卷：378
• 期：9808
• 页码：1997-2004
• 全文大小：1144 K

文摘

Summary

Background

Tracheal tumours can be surgically resected but most are an inoperable size at the time of diagnosis; therefore, new therapeutic options are needed. We report the clinical transplantation of the tracheobronchial airway with a stem-cell-seeded bioartificial nanocomposite.

Methods

A 36-year-old male patient, previously treated with debulking surgery and radiation therapy, presented with recurrent primary cancer of the distal trachea and main bronchi. After complete tumour resection, the airway was replaced with a tailored bioartificial nanocomposite previously seeded with autologous bone-marrow mononuclear cells via a bioreactor for 36 h. Postoperative granulocyte colony-stimulating factor filgrastim (10 ¦Ìg/kg) and epoetin beta (40?00 UI) were given over 14 days. We undertook flow cytometry, scanning electron microscopy, confocal microscopy epigenetics, multiplex, miRNA, and gene expression analyses.

Findings

We noted an extracellular matrix-like coating and proliferating cells including a CD105+ subpopulation in the scaffold after the reseeding and bioreactor process. There were no major complications, and the patient was asymptomatic and tumour free 5 months after transplantation. The bioartificial nanocomposite has patent anastomoses, lined with a vascularised neomucosa, and was partly covered by nearly healthy epithelium. Postoperatively, we detected a mobilisation of peripheral cells displaying increased mesenchymal stromal cell phenotype, and upregulation of epoetin receptors, antiapoptotic genes, and miR-34 and miR-449 biomarkers. These findings, together with increased levels of regenerative-associated plasma factors, strongly suggest stem-cell homing and cell-mediated wound repair, extracellular matrix remodelling, and neovascularisation of the graft.

Interpretation

Tailor-made bioartificial scaffolds can be used to replace complex airway defects. The bioreactor reseeding process and pharmacological-induced site-specific and graft-specific regeneration and tissue protection are key factors for successful clinical outcome.

Funding

European Commission, Knut and Alice Wallenberg Foundation, Swedish Research Council, StratRegen, Vinnova Foundation, Radiumhemmet, Clinigene EU Network of Excellence, Swedish Cancer Society, Centre for Biosciences (The Live Cell imaging Unit), and UCL Business.